Barriers and facilitators to mexican-american participation in clinical trials physician and patient focus group perspectives英文文献资料.docVIP

Vol.2, No.7, 742-752 (2010) Health doi:10.4236/health.2010.27113 Barriers and facilitators to mexican-american participation in clinical trials: physician and patient focus group perspectives Jesse Nodora , Tomas Nu?o , Ken O’Day , Virginia Yrun , Francisco Garcia * 1 2 3 2 2 1 2 National Center of Excellence in Women’s Health and the Arizona Cancer Center, University of Arizona, Tucson, USA National Center of Excellence in Women’s Health and the Mel and Enid Zuckerman College of Public Health, University of Arizona, Corresponding Author: fcisco@ Xcenda, Palm Harbor, USA Tucson, USA; 3 * Received 16 March 2010; revised 21 April 2010; accepted 22 April 2010. ABSTRACT recruitment as the most pressing issue in the conduct of clinical trials [1]. Difficulty in recruiting participants increases the time it takes to complete clinical trials, delays approval of new medications, and reduces incen- tives for drug development. Recruitment appears to be particularly challenging among racial/ethnic minority populations, and these groups tend to be seriously un- derrepresented in clinical trials [2]. Under representation of minority populations in clinical trials limits our un- derstanding of the wide range of biological, social, and cultural factors that influence treatment response and reduces the generalizability of new treatments to minor- ity groups; it thus may contribute to health disparities [3, 4]. Also, as a matter of equity, those suffering from dis- ease should have access to new and promising treat- ments through clinical trials, regardless of their racial and ethnic identities. As part of the National Institutes of Health Revitaliza- tion Act of 1993, the United States Congress mandated that women and minorities be included in clin